{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:41:44Z","timestamp":1763746904501},"reference-count":21,"publisher":"Wiley","issue":"S52","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":6749,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1990,11]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> 23 newly diagnosed patients affected by cutaneous T\u2010cell lymphoma were treated with sub\u2010cutaneous interferon alpha\u20102a to evaluate the therapeutic efficacy and the toxicity of this agent. IFN was administered daily with dose escalation from 3 to 18 million units for 12 weeks; thereafter, patients induced into complete (CR) or partial (PR) remission were given IFN at maximal tolerated dose 3 times weekly for 6 or 9 months. The objective tumor response was observed in 17 patients (74%): 8 (35%) were CR and 9 (39%) were PR. A 74\u2010yr\u2010old patient died because of neutropenia and sepsis at the end of induction phase, while receiving IFN at dose of 18 million units. Disease stage is the initial feature predictive of response to IFN therapy. The dose schedule of this study was well tolerated: only 3 patients developed liver toxicity, while leukopenia was evident in 6 patients. Only 2 CR patients have relapsed, 18 and 24 months from response; the remaining 6 CR patients are in continuous complete remission with a median follow\u2010up of 41.8 months. 6 PR patients have progressed from 8 to 17 months after response, and in the 3 PR patients not yet progressed the response duration ranges from 20 to 24 months. In conclusion, interferon alpha\u20102a is a very effective agent in therapy of untreated cutaneous T\u2010cell lymphoma with an overall response rate of 74%.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1990.tb00903.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T10:30:21Z","timestamp":1279449021000},"page":"32-35","source":"Crossref","is-referenced-by-count":25,"title":["Interferon alpha\u20102a in cutaneous T\u2010cell lymphoma"],"prefix":"10.1111","volume":"45","author":[{"given":"M. L.","family":"Vegna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Papa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Defazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"De Pit\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Puddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ferranti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Simoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mandelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(63)90056-1"},{"key":"e_1_2_1_3_2","first-page":"548","article-title":"Cutaneous T cell lymphomas: perspective","volume":"83","author":"Edelson RL.","year":"1975","journal-title":"Ann Intern Med"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197712)40:6<2851::AID-CNCR2820400615>3.0.CO;2-X"},{"key":"e_1_2_1_5_2","first-page":"270","volume-title":"Cutaneous Lymphoma","author":"Bunn PA","year":"1982"},{"key":"e_1_2_1_6_2","first-page":"681","article-title":"A 10\u2010year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total\u2010skin electron\u2010beam radiation therapy","volume":"63","author":"Vonderheid EC","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_7_2","first-page":"669","article-title":"Photochemotherapy for mycosis fungoides: long\u2010term follow\u2010up study","volume":"63","author":"Roenigk HH","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_8_2","first-page":"691","article-title":"Electron\u2010beam therapy for mycosis fungoides: the Stantford University experience","volume":"63","author":"Hoppe RT","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197501000-00004"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.1980.tb00883.x"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197712)40:6<2851::AID-CNCR2820400615>3.0.CO;2-X"},{"key":"e_1_2_1_12_2","first-page":"93","article-title":"Recombinant Luekocyte interferon alfa\u20102a in the treatment of mycosis fungoides","volume":"1","author":"Simoni R.","year":"1987","journal-title":"J Biol Regul Homeost Agents"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-93-3-399"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1182\/blood.V58.4.712.712","article-title":"Follow\u2010up obstervations on the effect of human leukocyte interferon on non\u2010Hodgkin's lymphoma","volume":"58","author":"Louie AC","year":"1981","journal-title":"Blood"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19860415)57:8 <1689::AID-CNCR2820571311>3.0.CO;2-M"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1982.03330190025025"},{"key":"e_1_2_1_17_2","first-page":"337","article-title":"Alpha recombinant interferon in the treatment of mycosis fungoides (MF)","volume":"72","author":"Tura S.","year":"1987","journal-title":"Haematologica"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V61.2.279.279"},{"key":"e_1_2_1_19_2","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood.V62.5.988.988","article-title":"Monoclonal antibody therapeutic trials in seven patients with T\u2010cell lymphoma","volume":"62","author":"Miller RA","year":"1983","journal-title":"Blood"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)92136-0"},{"issue":"1","key":"e_1_2_1_21_2","first-page":"188a","article-title":"Leukocyte interferon as a biological modifier in lymphoproliferative diseases resistant to standard therapy (abstract)","volume":"62","author":"Clark RH","year":"1983","journal-title":"Blood"},{"key":"e_1_2_1_22_2","first-page":"52","article-title":"The deficit in HLA expression in small cell lung cancer resides at the transcriptional level and is reversed by interferon (abstract)","volume":"3","author":"Doyle A.","year":"1984","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1990.tb00903.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1990.tb00903.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T23:21:52Z","timestamp":1698016912000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1990.tb00903.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,11]]},"references-count":21,"journal-issue":{"issue":"S52","published-print":{"date-parts":[[1990,11]]}},"alternative-id":["10.1111\/j.1600-0609.1990.tb00903.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1990.tb00903.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,11]]}}}